# 1. Financial Performance ## A. Key Figures * **Revenue:** ₹260 Cr Q3 FY'26 (+32%) · ₹733 Cr 9M FY'26 (+37%) * **Adjusted EBITDA:** ₹63 Cr Q3 FY'26 (+1%) · ₹175 Cr 9M FY'26 (+52%) * **Adjusted PAT:** ₹34 Cr Q3 FY'26 (13% margin) · ₹86 Cr 9M FY'26 (12% margin) * **Operating Cash Flow:** ₹153 Cr 9M FY'26 (65% of EBITDA) * Net Debt: **-₹283.6 Cr** (cash surplus) ## B. Revenue Growth * **Sustained Scaling:** Revenue growth reflects strong momentum from increased patient volumes, higher RPT, and successful business expansion over recent years. * **Diversified Drivers:** 9-month performance underscores operating discipline and benefits from a diversified operational footprint. ## C. EBITDA & Margins * **Operating Leverage Realized:** Significant EBITDA expansion over prior years highlights strong operating leverage, despite near-term margin pressure in 9M due to strategic investments. * **Margin Dynamics:** Adjusted EBITDA margin decline in 9M reflects **strategic costs in Saudi Arabia**, partially offset by efficiency gains; Q3 margin stabilized at 3%. ## D. Profit After Tax * **Inflection Confirmed:** Transition from loss to profit marks a clear turnaround, with adjusted PAT more than doubling year-on-year on improved margins and scale. * **Clean Earnings Base:** 9-month PAT excludes **₹4 crore** in non-recurring items (CCPS conversion, Saudi setup), highlighting underlying profitability strength. ## E. Cash Flow Conversion * **Capital Efficiency:** Strong cash conversion at **65% of EBITDA** demonstrates disciplined capital allocation and a founder-led focus on cash realizations. * **Self-Sustaining Growth:** Negative net debt position provides financial flexibility to fund global expansion without reliance on external financing. --- # 2. Patient & Treatment Volumes ## A. Key Figures * **Patient Volume:** **33,076** in FY '25 (+20% CAGR from FY '23) · **36,550** in 9M FY '26 (+15% YoY) ## B. Patient Count Trends * **Scaled Platform Play:** Business model emphasizes consolidated patient and treatment volumes over clinic count or geographic splits, reflecting a unified operational platform. * **Expanding Access:** 16-year focus on patient-centric care and clinical excellence has driven penetration in Tier-2 and Tier-3 cities, capturing underserved demand. * **Growth Trajectory:** Strong double-digit patient volume growth reflects sustained scaling and market leadership in emerging markets. ## C. Treatment Volume Growth * **Volume-Driven Revenue Model:** Revenue generation is directly tied to **session volume** and **revenue per treatment (RPT)**, with session count being a critical KPI. * **Market Tailwinds:** Underlying dialysis demand in India projected to grow at **7% CAGR**, fueled by **over 3 lakh new ESRD cases annually**. * **Operating Leverage Inflection:** Business reached scale after 11 years of EBITDA losses, now benefiting from improved utilization and fixed-cost absorption. ## D. Session Utilization Rates * **Capacity-Constrained Model:** Each machine supports only **3 sessions per day** due to 5-hour session length (4-hour treatment + prep/recovery), creating a fixed-capacity dynamic akin to airlines. --- # 3. Revenue Mix & Pricing ## A. Key Figures * **International Revenue Mix:** **41%** of total (9M FY26) vs. **12%** (FY23) * **Revenue per Treatment (RPT):** **₹2,275** (FY25) → **₹2,574** (9M FY26, +17% YoY) · **₹2,642** (Q3 FY26, +12% YoY) ## B. International Revenue Mix * **Strategic Geographic Shift:** Significant and sustained expansion into higher-margin international markets has reshaped revenue composition, with international now contributing a majority-share of incremental growth. * **Margin Accretion Expected:** Higher international mix is structurally favorable for margins and ROCE, leveraging India’s operating platform while capitalizing on elevated pricing in target geographies. * **Captive Model Economics:** In captive partnerships, **revenue share ranges from 10% to 18%** with no rent obligations, terms varying by geography, volume, and scope—supporting scalable, asset-light growth. ## C. Revenue per Treatment * **Strong RPT Expansion:** Blended RPT growth reflects successful international scaling and pricing power, with **double-digit year-on-year improvements** driven by mix shift and selective price increases. * **Pricing Dynamics:** Recent RPT tailwinds include **price hikes in the Philippines (Oct 2024)** and **CGHS revision in India**, though the latter has limited system-wide impact due to small patient base. * **India RPT Discipline:** New Indian clinics are priced near the **$20/session** benchmark—the world’s lowest—ensuring affordability and volume growth, while international markets (e.g., **Philippines: ~$110**, **Uzbekistan: ~$55**) drive the blended uplift. --- # 4. Clinic Network & Expansion ## A. Key Figures * **Captive Partnerships:** **300+** private hospitals partnered * **Geographic Reach:** **25 states, 290+ cities** across India * **Market Share:** ~**50%** of India’s organized dialysis market * **Clinic Size:** **11 beds** average per clinic in India * **PPP Projects:** **4 states** active (Andhra Pradesh, Bihar, Uttarakhand, Karnataka) * **International Presence:** **Philippines** (3rd largest network), **Uzbekistan**, and **Saudi Arabia** (JV in progress) ## B. Captive Clinic Growth * **Core Growth Engine:** Captive “shop-in-shop” model dominates operations, enabling rapid scalability in Tier-2/3 markets by leveraging hospital infrastructure and paramedical staffing. * **Network Design Driven by Access:** Expansion prioritizes patient proximity, necessitating a decentralized footprint of small-to-medium clinics due to real estate constraints and 85% utilization cap for emergencies. * **Leadership Consolidation:** NephroPlus is executing on RHP-aligned expansion plans, focusing on brownfield takeovers, greenfield setups, and optimizing existing clinic volumes to deepen penetration. * **Structural Advantage:** Long-term contracts (12–14 years) and **high captive renewal rates in the high 90% range** ensure revenue visibility and stability. ## C. PPP & Brownfield Expansion * **Selective, High-Quality PPP Strategy:** Only **4 PPPs in 16 years**, pursued opportunistically with focus on quality, cost efficiency, and ROCE—resulting in near-**100% contract renewal rates** and strong margins. * **Third Growth Lever:** Strategic acquisitions, large PPPs, or new market entries remain key but uncertain; proven ability to scale post-transition demonstrated in Philippines and Uzbekistan. ## D. International Market Entry * **Proven International Scalability:** Achieved top-three position in the Philippines within five years via acquisition-led entry, now advancing toward market leadership. * **Structured Market Selection Framework:** Expansion guided by demand scale, reimbursement clarity, regulatory stability, and repatriation rules—ensuring disciplined capital allocation. * **Saudi JV Progressing:** Two-year-old joint venture with Tibbiyah advancing through licensing phase, operating under captive model with **$300 average treatment cost** and path to margin accretion. --- # 5. Operational Efficiency ## A. Key Figures * **Capital Investment per Bed:** **₹9–11 lakhs** (consistent across models) * **Machine Lifespan Extension:** **3–4 years** beyond industry norms via refurbishment ## B. Cost per Bed * **Scalable Model:** Dialysis standardization enables distributed scaling and operating leverage, with cost control critical due to complex cost structures. * **Competitive Cost Structure:** Leading consumables efficiency through direct global sourcing, contract manufacturing, and optimal usage drives margin resilience. * **Technology-Driven Oversight:** Proprietary systems minimize overheads in quality, operations, and financial audits across the **NephroPlus** network. * **Unit Economics Discipline:** Standardized capital deployment ensures consistent margin outcomes and scalability across new clinics. ## C. Biomedical Maintenance * **Cost and Quality Advantage:** In-house biomedical teams reduce maintenance costs through preventive care, internal spare parts logistics, and extended machine life. * **Infection Control Innovation:** Proprietary system virtually eliminates cross-infections (historically affecting **one-third of patients**), enhancing clinical outcomes and trust. ## D. Staffing Model * **Self-Sustaining Workforce:** Dedicated training academies ensure steady supply of paramedical staff, while performance-based retention optimizes clinic-level productivity. * **Staffing Pyramid Efficiency:** Structured career progression and attrition management maintain high engagement and operational consistency across the network. --- # 6. Risks & Margin Pressures ## A. Margin Structure & Market Dynamics * **Dialysis Margin Challenge:** Sustainable margins in dialysis require massive scale and full operational focus due to high fixed costs; lack of scale renders profitability unviable regardless of pricing. * **Hospital Economics:** Indian hospitals do not profit from dialysis and prioritize high-margin acute care (CONGO); dialysis is offered to support nephrologist networks and drive returns from transplants, ICU, labs, and pharmacy. * **Unorganized Market Shift:** 80% of India’s dialysis market remains fragmented, but gradual consolidation is underway as hospitals lack scale to operate efficiently. * **India as Margin Laboratory:** NephroPlus’s global margin strength stems from a 16-year-optimized platform built to operate profitably at **$20 per session**, the world’s lowest price point. * **Model Parity:** All three operational models—standalone, captive, and PPP—deliver **very similar margin profiles and returns**, supporting strategic flexibility. ## B. Expansion & Execution Risk * **New Market Margin Impact:** Entry into new geographies may pressure margins by **100–150 bps** in year one due to setup costs, but operating leverage from existing markets supports **stable, healthy long-term margins**. * **International Synergy Advantage:** Global margins exceed local peers due to **India-driven operational synergies**, though country-specific breakdowns are not disclosed. * **Execution Timing Uncertainty:** Clinic roll-out may see quarterly spillovers, warranting **annualized performance assessment** despite confidence in full-year targets. * **Saudi Ramp-Up Visibility:** Initial investments and team building in Saudi Arabia will take **several quarters** to yield clear financial impact. ## C. Pricing & Partner Discipline * **Selective Partnership Management:** NephroPlus terminates relationships with **poor-paying hospital partners**, prioritizing **quality of earnings** and sustainable growth over volume. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue CAGR Guidance:** **15%-20%** over 3–4 years * **International Revenue Contribution:** **41%** (ex-Saudi) · **60%-70%** long-term potential * ROCE: 10% in FY '24 → 18.7% in FY '25 · 24.7% annualized expected in FY '26 * Adjusted Margin: **24.3%** (ex-Saudi setup costs) * **Capex Range:** **₹100–125 Cr** historically ## B. Revenue Growth Framework * **Three-Pillar Growth Engine:** Expansion driven by **ramp-up of existing clinics**, **roll-ups in current markets**, and **selective new country entries or large PPPs**, with the latter being high-impact but lumpy. * **No Short-Term Guidance:** Company refrains from annual guidance due to **unpredictability of large international forays**, despite high visibility into near-term revenue from existing capacity and patient volumes. * **Sustainable Trajectory:** Management expects growth to stabilize within the 15%-20% CAGR band, signaling a shift from hyper-growth to **durable, predictable scaling**. ## C. Capital Allocation & Expansion Discipline * **ROCE-Centric Strategy:** All investments—organic or inorganic—are evaluated primarily on **ROCE accretion**, with proven success in projects like Uzbekistan’s PPP. * **Measured Geographic Expansion:** Strategic market entries targeted every 1–2 years in 1–2 geographies, emphasizing **clinical quality and brand integrity** over speed. * **Capital Efficiency:** Capex expected to remain within historical range, supporting a **"marathon, not a sprint"** philosophy to ensure operational bandwidth and sustainable returns. ## D. Long-Term International Mix * **Global Platform Play:** Leverages 16 years of Indian operating experience and cost advantage ($22 price point) to achieve **higher margins and ROCE in international markets** versus local peers. * **Gradual Internationalization:** While India remains dominant, international revenue is on a **slow, steady upward trajectory**, with 60%-70% a long-term possibility—though no timeline is set. * **Market Entry Filters:** New geographies assessed on **patient volume, reimbursement, stability, and profit repatriation**, ensuring de-risked, strategic expansion. * **Saudi Arabia Catalyst:** Revenue expected to commence in a couple of quarters post-license, marking the **first return on a 2-year investment** and a key inflection for international growth.